Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Hellmann, M. D. [1 ]
Rizvi, N. [1 ]
Gettinger, S. N. [2 ]
Goldman, J. [3 ]
Chow, L. Q. [4 ]
Juergens, R. [5 ]
Borghaei, H. [6 ]
Brahmer, J. [7 ]
Shen, Y. [8 ]
Harbison, C. T. [9 ]
Nathan, F. [10 ]
Ready, N. E. [11 ]
Antonia, S. J. [12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] Yale Comprehens Canc Ctr, Med Oncol, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Hematol Oncol, Los Angeles, CA 90024 USA
[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[5] Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
[6] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Oncol, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Immunosci Metab Dis & Fibrosis, Princeton, NJ USA
[10] Bristol Myers Squibb Co, Clin Res, Princeton, NJ USA
[11] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[12] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31738-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3097
引用
收藏
页码：S632 / S633
页数：2
相关论文
共 50 条
  • [41] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
    Reck, Martin
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [43] Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
    Alessi, J.
    Elkrief, A.
    Ricciuti, B.
    Cortellini, A.
    Wang, X.
    Vaz, V. R.
    Barrichello, A.
    Lamberti, G.
    Fulgenzi, C.
    Pecci, F.
    Pinato, D. J.
    Schoenfeld, A. J.
    Awad, M. M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S358 - S359
  • [44] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Helias-Rodzewicz, Zofia
    Dumoulin, Jennifer
    Giraud, Violaine
    Labrune, Sylvie
    Chinet, Thierry
    Emile, Jean-Francois
    Giroux-Leprieur, Etienne
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [45] Dual-organ toxicity during treatment with nivolumab and ipilimumab in combination with chemotherapy in the first-line treatment of non-small cell lung cancer
    Dyzma-Kasprzak, Agnieszka
    Kasprzak, Karol
    Szczepaniak-Wojtowicz, Elzbieta
    Milanowska, Joanna
    Chmielewska, Izabela
    Krawczyk, Pawel
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [46] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [47] First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study
    Imai, Hisao
    Kijima, Takashi
    Azuma, Koichi
    Kishi, Kazuma
    Saito, Haruhiro
    Yamaguchi, Teppei
    Tanizaki, Junko
    Yoneshima, Yasuto
    Fujita, Kohei
    Watanabe, Satoshi
    Kitazono, Satoru
    Fukuhara, Tatsuro
    Hataji, Osamu
    Toi, Yukihiro
    Mizutani, Hideaki
    Hamakawa, Yusuke
    Maemondo, Makoto
    Ohsugi, Tomoyuki
    Suzuki, Keisuke
    Horinouchi, Hidehito
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (04) : 452 - 462
  • [48] Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
    Ramalingam, Suresh S.
    Hellmann, Matthew D.
    Awad, Mark M.
    Borghaei, Hossein
    Gainor, Justin
    Brahmer, Julie
    Spigel, David R.
    Reck, Martin
    O'Byrne, Kenneth J.
    Paz-Ares, Luis
    Zerba, Kim
    Li, Xuemei
    Geese, William J.
    Green, George
    Lestini, Brian
    Szustakowski, Joseph D.
    Chang, Han
    Ready, Neal
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
    Peters, S.
    Ramalingam, S. S.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S-W.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Nathan, F. E.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2019, 30 : 913 - +
  • [50] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
12345